With three distinct, proprietary programs in HCV therapeutics, Achillion is uniquely positioned to meet the market challenges associated with the increasing disease burden of HCV infection.

Achillion is a leading-edge pharmaceutical company advancing multiple candidates with novel mechanisms of action - critical to the discovery of new treatments for patients with infectious disease.

Achillion's proven discovery and development teams continually apply their deep understanding of virology, microbiology and synthetic chemistry to the development of potentially best-in-class drug candidates.

Achillion Pharmaceuticals is an innovative leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases.

Achillion is focused on discovery and development of innovative drugs for the most challenging problems in infectious disease - hepatitis C and resistant bacterial infections.